Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment

Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced that the Company has signed a biomanufacturing services agreement with Minnesota-based Biomedical Frontiers Incorporated for the production of an iron chelating agent used in the treatment of thalassemia, an inherited blood disorder.

Toronto, ON (PRWEB) November 28, 2008 - Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced that the Company has signed a biomanufacturing services agreement with Minnesota-based Biomedical Frontiers Incorporated for the production of an iron chelating agent used in the treatment of thalassemia, an inherited blood disorder.

Therapure Biopharma will apply experience gained previously in the production of Biomedical Frontiers' deferoxamine conjugates, which are injectable iron-binding drugs used to neutralize iron build-up in the blood of patients with an iron overload disorder. Biomedical Frontiers believes that their product offers advantages over existing treatments for thalassemia that will result in improved patient compliance and therefore better clinical outcomes.

Production of this compound for Biomedical Frontiers is a great example of the flexibility of our modern biomanufacturing facility

We are able to produce the necessary supplies of their compound quickly to support the continuing clinical development of this important new product.

We previously contracted with Therapure Biopharma in the manufacture of drug material to support our successful development program

"Production of this compound for Biomedical Frontiers is a great example of the flexibility of our modern biomanufacturing facility," said Thomas Wellner. "We are able to produce the necessary supplies of their compound quickly to support the continuing clinical development of this important new product."

"We previously contracted with Therapure Biopharma in the manufacture of drug material to support our successful development program", said Bo Erik Hedlund, President and Chief Executive Officer of Biomedical Frontiers. "Because of this earlier experience, we are very confident in Therapure Biopharma's ability to produce a high-quality product within the timelines we need to start our Phase II trials. Securing both a manufacturer and a financial contribution from Therapure Biopharma will make it much easier for us to acquire the additional funding we need to complete these studies and bring a more effective and user-friendly treatment for thalassemia and other iron overload disorders to markets."

About Therapure Biopharma:

Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. Therapure Biopharma acquired its Canadian-built and conceived facility from Hemosol Corporation, a specialist in therapies derived from hemoglobin, a blood protein. Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market.

For more information, please visit: www.therapurebio.com

About Biomedical Frontiers, Incorporated:

Biomedical Frontiers Incorporated ("BMF or the Company") is a privately held biopharmaceutical company with a focus on developing innovative iron-binding drugs for the treatment of iron overload disorders and acute iron poisoning. BMF's proprietary technical platform involves chemical coupling of drugs to biocompatible polymers. The Company is currently preparing for a Phase II clinical trial for its proprietary lead iron-binding drug, starch-conjugated deferoxamine, in patients with transfusion dependent thalassemia.

For more information, please contact: Bo Hedlund, Ph.D. 612-281-4033

###

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/RW1wdC1Qcm9mLUVtcHQtTG92ZS1Mb3ZlLVNpbmctWmVybw==

therapure biopharma biomanufacturing biomedical frontiers biopharmaceuticals thalassemia

Bookmark -  Del.icio.us | Furl It | Technorati | Ask | MyWeb | Propeller | Live Bookmarks | Newsvine | TailRank | Reddit | Slashdot | Digg | Stumbleupon | Google Bookmarks | Sphere | Blink It | Spurl